FAQ: UCLA's $2M Grant for MRI-Guided Cancer Radiation Therapy Research
Summary
UCLA Health received a $2 million grant from ViewRay Systems to accelerate research on MRI-guided radiation therapy for targeted cancer treatment. This funding is part of broader industry efforts to improve cancer therapies, with companies like Soligenix Inc. also investing in similar advancements.
What is the main purpose of the $2 million grant awarded to UCLA Health?
The grant from ViewRay Systems is intended to accelerate UCLA’s research efforts in leveraging MRI-guided radiation therapy to provide targeted treatment for cancer patients.
Who provided the funding for this cancer research initiative?
The $2 million grant was awarded by ViewRay Systems, a for-profit company, to support UCLA Health’s research on MRI-guided radiation therapy.
Why is this research on MRI-guided radiation therapy significant?
This research is significant because it represents ongoing efforts to improve cancer treatment methods, with MRI-guided therapy potentially offering more targeted and effective treatment options for cancer patients.
Are other companies besides ViewRay Systems investing in similar cancer treatment research?
Yes, according to the content, many other companies like Soligenix Inc. (NASDAQ: SNGX) are also investing in ways to improve how cancer is treated.
Where can readers find more information about this specific research grant?
Readers can find more information by clicking Read More» or visiting the UCLA Health news release at this link.
What organization published this information about the research grant?
This information was published by BioMedWire (BMW), a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences developments, which is part of the Dynamic Brand Portfolio at IBN.
How can people stay updated on similar developments in biotechnology and biomedical sciences?
People can receive SMS alerts from BioMedWire by texting “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) or visit https://www.BioMedWire.com for more information.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 213027